# Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

> **NCT06470971** · PHASE2 · RECRUITING · sponsor: **Yuanquan Yang** · enrollment: 40 (estimated)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Hematopoietic and Lymphatic System Neoplasm

## Interventions

- **BIOLOGICAL:** Anti-PD-L1 Monoclonal Antibody
- **BIOLOGICAL:** Anti-PD1 Monoclonal Antibody
- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Scan
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **OTHER:** Quality-of-Life Assessment
- **BIOLOGICAL:** Siltuximab

## Key facts

- **NCT ID:** NCT06470971
- **Lead sponsor:** Yuanquan Yang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-09
- **Primary completion:** 2026-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06470971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06470971, "Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06470971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*